Diffregen is developing Angiocidin and a new class of therapeutics that provide a novel approach for activating the immune system against cancer. In healthy monocytes, Angiocidin leads to immune stimulating cytokine release and macrophage differentiation; in leukemia cells, this induces terminal differentiation and blocks growth. Angiocidin shows great potential as a breakthrough therapeutic for Acute Myeloid Leukemia.